The purpose of this randomized control trial is to compare how food cravings, food selection, and food consumption change in response to frequent food advertisements compared to non-food advertisements in adults taking GLP-1 (weight loss) medications. The primary question we aim to answer is: do GLP-1 medications reduce an individual's vulnerability to external triggers that drive food cravings and consumption?
Participants will:
* report daily food consumption for a total of 10 days, * receive eight daily prompts to view food or non-food related advertisements, and respond to a short 9-question survey for 7 days, * answer several questionnaires, * and complete two in-person visits to complete a virtual reality food selection task.
Adults (18+) with overweight or obesity (BMI >25 kg/m2)
On an injectable form of tirzepatide GLP-1 medication at a minimum dose of 7.5 mg, taking it as prescribed by their doctor
Not currently taking an incretin-based medication at baseline other than the GLP-1 medication
Fluent in English
Do not have consistent access to a smart phone that can access the study software
Diagnosed with cognitive or physical disability or epilepsy
Adults taking a compound GLP-1
Penn State University
Lead sponsor
Penn State Health
Collaborator